New hope for stomach cancer: triple therapy trial launches
NCT ID NCT06093425
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This phase 3 trial tests whether adding TST001 (a drug targeting a protein found on stomach cancer cells) to standard chemotherapy and immunotherapy can help people with advanced stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 820 adults who have not had prior treatment will receive either TST001 or a placebo, plus pembrolizumab and chemo. The study aims to see if the combination slows tumor growth and improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.